Manufacturing Cellares and Papillon partner for PPL-001 manufacturing automation Pharmaceutical Business ReviewPPL-001 is a gene-corrected haematopoietic stem and progenitor cell (HSPC) therapy.Read full story pharminent July 22, 2026 (Last updated: July 27, 2026) Pharmaceutical Business Review PPL-001 is a gene-corrected haematopoietic stem and progenitor cell (HSPC) therapy. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Novo Nordisk Sues Eli Lilly Over ‘Deceptive’ GLP-1 AdvertisingNext: US generic tariff reprieve on the rocks as Trump proposes 100% rate in 2028 Related Stories Manufacturing Trump Threatens 100%–200% Tariffs on Imported Generic Drugs pharminent July 22, 2026 Manufacturing Speciality versus diversity: the four-way CDMO race in outsourced HPAPI manufacturing pharminent July 22, 2026 Manufacturing Samsung Biologics: geographic diversification is a sound business decision pharminent July 22, 2026
